MB 1
BULLETS
Free CME
Join now
Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 213799

Testing and Screening QID: 213799 (M1.OMB.20.4730)
In scope icon N/A A
QID 213799 (Type "213799" in App Search)
A phase 3 clinical trial is testing the efficacy of a novel checkpoint inhibitor as immunotherapy for metastatic melanoma with central nervous system involvement. The study enrolled 350 patients, 150 of whom were randomized to receive the novel checkpoint inhibitor. The primary endpoint of the study was mortality at 1 year. For the experimental group, the median survival was 13.6 months, and the number of subjects surviving at 1 year was 90. For the control group receiving standard treatment, the median survival was 11.9 months, and the number of subjects surviving at 1 year was 80. Which of the following represents the absolute risk reduction of this experimental drug?
Type in at least one full word to see suggestions list